Related Experiment Video
Updated: May 2, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Molecular profiling of non-small cell lung cancer]
L Gibault1, A Cazes2, C Narjoz3
1Service de pathologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France.
Abstract:
The management of locally advanced and metastatic non-small cell lung cancer has been revolutionized thanks to recent progress in pathology and molecular biology. The first molecular subgroup is defined by activating mutations of the epidermal growth factor receptor (EGFR), and a dramatic response to specific tyrosine kinase inhibitors. Since then, multiple genetic alterations (KRAS, HER2, BRAF, PIK3CA, ALK, ROS, RET…) have been identified as potential target of novel therapies, and molecular profiling has become common practice. This review focus on the molecular alterations associated with non-small cell lung cancer, including molecular profiling and response to targeted therapies.
Insights
Recent advances in molecular biology have transformed non-small cell lung cancer (NSCLC) treatment. Identifying specific genetic alterations, like epidermal growth factor receptor (EGFR) mutations, guides targeted therapies and improves patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Management of locally advanced and metastatic non-small cell lung cancer (NSCLC).
- Revolutionary progress driven by pathology and molecular biology insights.
- Established role of molecular profiling in routine clinical practice.
Purpose:
- To review key molecular alterations in NSCLC.
- To discuss the impact of molecular profiling on treatment selection.
- To highlight the response to targeted therapies based on genetic profiles.
Summary:
- Identifies activating mutations in epidermal growth factor receptor (EGFR) as a primary molecular subgroup.
- Details various other genetic alterations (KRAS, HER2, BRAF, PIK3CA, ALK, ROS, RET) as therapeutic targets.
- Emphasizes the clinical utility of molecular profiling for NSCLC management.
Impact:
- Personalized treatment strategies for NSCLC patients.
- Improved patient outcomes through targeted therapy selection.
- Advancement of precision medicine in lung cancer care.
